Retrophin Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SAN DIEGO , Aug. 14, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that its Compensation Committee granted inducement awards pursuant to Rule 5635(c)(4) of the NASDAQ Listing...
View ArticleRetrophin Announces Cooperative Research and Development Agreement with NCATS...
SAN DIEGO , Sept. 05, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that it has entered into a three-way Cooperative Research and Development Agreement (CRADA) with the...
View ArticleRetrophin to Present at September Investor Conferences
SAN DIEGO , Sept. 11, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage , chief executive officer, will present at two upcoming investor conferences in New...
View ArticleRetrophin Announces Presentation of New Data from Physician-Initiated...
Patient with PKAN showed persistent improvement in function over 30-month period of treatment with fosmetpantotenate SAN DIEGO , Oct. 05, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today...
View ArticleRetrophin to Present New Data for Sparsentan at ASN Kidney Week 2017
SAN DIEGO , Oct. 13, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced that it will present new data from the open label extension portion of the Phase 2 DUET study of sparsentan...
View ArticleRetrophin to Report Third Quarter 2017 Financial Results
SAN DIEGO , Oct. 24, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report third quarter 2017 financial results on Tuesday, November 7, 2017 after the close of the U.S....
View ArticleRetrophin to Present at the Jefferies 2017 London Healthcare Conference
SAN DIEGO , Nov. 02, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage , chief executive officer, will present at the Jefferies 2017 London Healthcare...
View ArticleRetrophin Reports Additional Positive Data from Open-Label Extension of Phase...
Progressive reduction in proteinuria and stable eGFR observed in open-label treatment period Findings presented at ASN Kidney Week 2017 SAN DIEGO , Nov. 03, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc....
View ArticleRetrophin Reports Third Quarter 2017 Financial Results
Phase 3 FORT Study of fosmetpantotenate continues to enroll PKAN patients Third quarter revenues increased 19 percent to $40 million SAN DIEGO, CALIFORNIA -- (Marketwired) -- 11/07/17 -- Retrophin,...
View ArticleRetrophin to Present at the BMO 2017 Prescriptions for Success Healthcare...
SAN DIEGO , Nov. 30, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage , chief executive officer, will present at the BMO 2017 Prescriptions for Success...
View ArticleRetrophin to Present at the 36th Annual J.P. Morgan Healthcare Conference
SAN DIEGO , Dec. 28, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage , chief executive officer, will present at the 36th Annual J.P. Morgan Healthcare...
View ArticleRetrophin and Censa Pharmaceuticals Enter into Strategic Collaboration to...
Retrophin obtains exclusive option to purchase Censa post proof-of-concept study Phase 2 proof-of-concept study in PKU patients expected to commence in mid-2018 SAN DIEGO , Jan. 05, 2018 (GLOBE...
View ArticleRetrophin Provides Corporate Update and 2018 Outlook
Preliminary full-year 2017 revenue of approximately $155 million SAN DIEGO , Jan. 08, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that, based on preliminary and unaudited...
View ArticleRetrophin to Present at the Leerink Partners 7th Annual Global Healthcare...
SAN DIEGO , Feb. 01, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage , chief executive officer, will present at the Leerink Partners 7th Annual Global...
View ArticleRetrophin to Report Fourth Quarter and Full Year 2017 Financial Results
SAN DIEGO , Feb. 13, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report fourth quarter and full year 2017 financial results on Tuesday, February 27, 2018 after the...
View ArticleRetrophin Reports Fourth Quarter and Full Year 2017 Financial Results
Company gains alignment to proceed on Subpart H accelerated approval pathway for sparsentan in FSGS; Study start-up activities ongoing to initiate Phase 3 pivotal trial in second quarter of 2018...
View ArticleRetrophin to Present at the Barclays Global Healthcare Conference
SAN DIEGO , Feb. 28, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage , chief executive officer, will present at the Barclays Global Healthcare Conference in...
View ArticleRetrophin Announces Appointment of Casey Logan as Vice President of Corporate...
SAN DIEGO , March 05, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Casey Logan has joined the Company as vice president, corporate development. Mr. Logan will report to...
View Article
